Tolerability and effectiveness of malaria chemoprophylaxis with mefloquine or chloroquine with or without co-medication

Journal of Travel Medicine

Volumn 4, Issue 3, 1997, Pages 121-127

  Handschin, Jürg C ^a   Wall, Michael ^b   Steffen, Robert ^c   Stürchler, Dieter ^d  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b University of Zürich ^*  (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; CARDIOVASCULAR AGENT; CHLOROQUINE; MEFLOQUINE; NEUROLEPTIC AGENT;

ARTICLE; CHEMOPROPHYLAXIS; DATA BASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALARIA; MALE; NAUSEA; NEUROTOXICITY; SKIN TOXICITY;

EID: 0030763335     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1997.tb00798.x     Document Type: Article

References (36)

1. LARIAM. Product monograph 1992;16-18.
2. World Health Organization. International travel and health. Vaccination requirements and health advice. Geneva:WHO, 1997.
3. Mittelholzer ML, Wall M, Steffen R. Malaria prophylaxis in different age groups. J Travel Med 1996;4:219-223.
4. Steffen R, Fuchs E, Schildknecht J, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet 1993;341:1299-1303.
5. Council for International Organizations of Medical Sciences (CIOMS). International reporting of adverse drug reactions. Final report of CIOMS working group. Geneva: CIOMS, 1990.
6. Schoch P, Burkard W. Interaction of mefloquine and its enantiomers with sigma and NMDA receptors. Roche Report, 1991.
7. Liu L, Katz Y, Weizman R, et al. Interactions of chloroquine with benzodiazepine, γ-aminobutyric acid and opiate receptors. Biochem Pharmacol 1991;41:1534-1536.
8. World Health Organization. Review of central nervous system adverse events related to the antimalarial drug, mefloquine (1985-1990). WHO/MAL/91-1063.
9. Sanders JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007-1016.
10. Hospitalization for epilepsy - United States, 1988-1992 [Editorial]. MMWR 1995;44:818-821.
11. LARIAM. International Standard Product Information, revised August 1994.
12. Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992;95:167-179.
13. Jallon P. Use of mefloquine in epileptic patients. J Neurol Neurosurg Psychiatry 1988;51:732.
14. Kerr L, Vanhauwere B. Review of adverse events associated with LARIAM (mefloquine) [Introduction, Jan 1, 1994]. Roche Report, 1994.
15. Kerr L, Vanhauwere B. Review of adverse events associated with LARIAM (mefloquine), Jan 1, 1994 to Dec 31, 1994. Roche Report, 1994.
16. Axmann A, Felegyhazi C, Huszar A, Juhasz P. Long-term malaria prophylaxis with Lariam in Cambodia, 1993. Travel Med Int 1994;12:13-18.
17. Davis TM, Dembo LG, Kaye-Eddie SA, et al. Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 1996;42:415-421.
18. Jaspers CAJJ, Hopperus Buma APCC, van Thiel PPAM, et al. Tolerance of mefloquine prophylaxis in Dutch military personnel. Am J Trop Med Hyg 1996;55:230-234.
19. Gerold M. Drug interaction study with mefloquine (Ro 21-5998/000) and beta-adrenoceptor blockers. Roche Research Report, 1987, B-101'873.
20. White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycaemia and hyperinsulinaemia in falciparum malaria. N EnglJ Med 1983;309:61-66.
21. Assan R, Perronne C, Chotard L, et al. Mefloquine-associated hypoglycaemia in a cachectic AIDS patient. Diabete Metab 1995;21:54-57.
22. Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability in chemoprophylaxis - focus on adverse event assessment, stereochemistry and compliance. Trop Med Int Health 1996;1:485-494.
23. Phillips M, Kass B. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996;3:40-45.
24. Weinke T, Trautmann M, Held T, et al. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45:86-91.
25. Karbwang J, Bunnag D, Breckenridge AM, Back DJ. The pharmacokinetics of mefloquine when given alone or in combination with sulphadoxine and pyrimethamine in Thai male and female subjects. Eur J Clin Pharmacol 1987;32: 173-177.
26. McIntosh IB, Power KG, Reed JM. Prevalence, intensity and sex differences in travel related stressors. J Travel Med 1996;3: 96-102.
27. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995;50:1-6.
28. Karbwang J, Looaereesuwan S, Back DJ, et al. Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women. Bull World Health Organ 1988;66:763-767.
29. Gupta KC, Joshi JV, Desai NK, et al. Kinetics of chloroquine & contraceptive steroids in oral contraceptive users during concurrent chloroquine prophylaxis. Indian J Med Res 1984; 80:658-662.
30. Wittes RC, Saginur R. Adverse reactions to mefloquine associated with ethanol ingestion. Can Med Assoc J 1995;152: 515-517.
31. Vuurman EFPM, Muntjewerff ND, Uiterwijk MMC, et al. Effects of mefloquine alone and with alcohol on psychomotor and driving performance. Eur J Clin Pharmacol 1996;50: 475-482.
32. ter Kuile FO, Luxemburger C, Nosten F, et al. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1995;89:660-664.
33. Boudreau EF, Fleckenstein L, Pang LW, et al. Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. Clin Pharmacol Ther 1990;48:399-409.
34. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 1990;4:264-279.
35. Sörgel F, Naber KG, Kinzi M, et al. Gastrointestinal recirculation on mefloquine in man. In: Abstracts, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sep 17-20, 1995, San Francisco, abstr. no. A78.
36. Behrens RH, Taylor RB, Low AS, et al. Traveller's diarrhea; a controlled study of its effect on chloroquine and proguanil absorption. Trans R Soc Trop Med Hyg 1994;88:86-88.